Weltruza for Schizophrenia: What Does FDA Approval

What changes with once-monthly injectable olanzapine?

The approval introduces a new formulation of an established antipsychotic. Weltruza releases olanzapine over a month after administration under the skin. Teva says treatment requires no loading dose or supplemental oral olanzapine at initiation. The company expects US availability in the weeks following its October 9 announcement; approval should therefore be distinguished from immediate access at every clinic. [Teva approval announcement](https://www.tevausa.com/news-and-media/press-releases/teva-announces-u.s.-food-and-drug-administration-fda-approval-of-weltruza-olanzapine-for-extended-re)

A significant practical difference concerns observation after treatment. The older intramuscular olanzapine product, Zyprexa Relprevv, requires observation for at least three hours after every injection because of post-injection delirium/sedation syndrome, which can cause confusion, profound sleepiness or coma. Weltruza has no mandatory observation requirement. This difference could make appointments easier to accommodate, although that practical benefit does not establish superior symptom control or eliminate the need for continuing clinical care. [Zyprexa Relprevv prescribing information](https://pi.lilly.com/us/zyprexa_relprevv.pdf)

What did the SOLARIS clinical trial show?

The randomized, double-blind phase of SOLARIS enrolled 675 adults with schizophrenia and compared three monthly injection doses with placebo. Its primary measure was change in the Positive and Negative Syndrome Scale, a clinician-rated assessment of schizophrenia symptoms. Teva reported statistically significant improvement versus placebo across all three doses. Because the comparison was with placebo, these findings do not demonstrate that Weltruza controls symptoms better than oral olanzapine or another long-acting antipsychotic. [SOLARIS efficacy announcement](https://www.tevausa.com/news-and-media/press-releases/teva-and-medincell-announce-positive-phase-3-efficacy-results-from-solaris-trial-evaluating-tev-749-ola/)

A subsequent open-label phase followed participants for up to another 48 weeks. Teva reported no suspected or confirmed post-injection delirium/sedation syndrome through week 56. That observation is reassuring, but an uncommon adverse event can remain undetected in a clinical development program. The prescribing information explicitly states that Weltruza's risk of this syndrome is currently unknown. Longer follow-up in routine practice will help clarify rare risks and whether simpler administration translates into better treatment continuity. [SOLARIS long-term safety report](https://www.tevausa.com/news-and-media/press-releases/new-long-term-safety-data-from-the-completed-phase-3-solaris-trial-support-the-potential-of-olanzapine-la/) [Weltruza prescribing information](https://www.weltruza.com/globalassets/weltruza/prescribing-information.pdf)

What safety checks remain important with Weltruza?

Monthly administration retains olanzapine's established safety concerns. Reported adverse effects include weight gain, sleepiness, constipation and injection-site reactions. Clinicians should monitor weight, fasting glucose and lipids before and during treatment. The label also warns about involuntary movements and neuroleptic malignant syndrome, a rare emergency. Weltruza carries a boxed warning about increased mortality in older adults with dementia-related psychosis and is not approved for that condition. [Weltruza prescribing information](https://www.weltruza.com/globalassets/weltruza/prescribing-information.pdf)

Choosing an injection should involve the patient's preferences, previous treatment response, side effects and ability to attend appointments. A useful consultation should address the benefit of fewer daily medication decisions alongside the continuing need for follow-up. Patients and clinicians should also agree on how to report emerging symptoms, arrange future injections and handle access problems. These practical questions will influence how useful the approval becomes for an individual patient.